Healthcare Industry News: S.A.
News Release - February 17, 2009
CorNova(R) Expands Management Team with Appointment of Robert Gallahue as Chief Financial Officer
Company Also Names Richard Sahagian as Senior ScientistBURLINGTON, Mass., Feb. 17 -- (Healthcare Sales & Marketing Network) -- CorNova®, Inc. today announced the expansion of its executive team with the appointment of Robert Gallahue as chief financial officer. The company also announced the addition of Richard Sahagian as senior scientist.
The appointments reflect the evolution of the company's endovascular product line, which includes the FiberHalo(TM) stent deployment and post-dilatation balloon catheter, the FiberHalo(TM) pre-dilatation balloon catheter and the advanced Valecor Platinum(TM) Coronary Stent System.
"We needed to put in place the financial expertise required to move CorNova® closer to becoming an advanced development and commercial organization," said S. Eric Ryan, M.D., CorNova®'s chief executive officer. "Bob's depth of financial experience and knowledge of the biomedical industry will be a significant contribution to the growth and maturation of the company."
Gallahue, 48, has more than 20 years of financial management experience with public and private biotechnology and medical technology companieS.A. various S.A.es of clinical and commercial development. He haS.A.so successfully participated in a variety of financial transactions, including initial public offerings, mergers, joint ventures, private placementS.A.d follow-on offeringS.A. a number of healthcare companies, including Molecular Insight Pharmaceuticals, Keryx BiopharmaceuticalS.A.d LeukoSite. He holdS.A. M.S.A. from Bentley College and a B.A. from Middlebury College.
Sahagian, 46, has more than 20 years of experience in medical device development and production. He will be responsible for production of the Valecor Platinum(TM) Coronary Stent (a platinum surface-modified stent), as well as manage the reS.A.ch and development of advanced surface modification technologies. Prior to joining CorNova®, Sahagian founded the medical device division at Implant Sciences Corp. He earned his B.S. from the University of Lowell.
About CorNova®
CorNova® iS.A.developer of next-generation endovascular products designed to integrate new technologies into existing productS.A.d procedures resulting in better patient outcomes without added procedure time, cost and patient risk. The company's FiberHalo(TM) stent deployment and post-dilatation balloon catheter is designed for stent deployment, lumen area measurement and post-dilatation to be performed with a single catheter. CorNova® iS.A.so developing a pre-dilatation form of the FiberHalo that can obtain information on arterial plaque composition allowing for better physician decision making and the Valecor Platinum(TM) Coronary Stent, a platinum surface-modified bare-metal stent, that has shown superior performance and anti-restenosis properties compared to current bare-metal stents. For more information, visit www.cornova.com.
Source: CorNova
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!